# Dose Escalation Study of Liposomal Paclitaxel With/Without Capecitabine in Patients With Advanced Gastric Carcinoma

> **NCT00639522** · PHASE1 · UNKNOWN · sponsor: **Nanjing Sike Pharmaceutical Co., Ltd.** · enrollment: 18 (estimated)

## Conditions studied

- Gastric Carcinoma

## Interventions

- **DRUG:** Liposomal paclitaxel and capecitabine

## Key facts

- **NCT ID:** NCT00639522
- **Lead sponsor:** Nanjing Sike Pharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2008-05
- **Primary completion:** 2009-09
- **Final completion:** 2009-12
- **Target enrollment:** 18 (ESTIMATED)
- **Last updated:** 2009-04-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00639522

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00639522, "Dose Escalation Study of Liposomal Paclitaxel With/Without Capecitabine in Patients With Advanced Gastric Carcinoma". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00639522. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*